JPRN-jRCT2033210424
Recruiting
未知
Postmarketing Surveillance Registry to evaluate safety and efficacy of Darvadstrocel for the treatment of complex perianal fistulas in Crohn's Disease Patients (J-INSPIRE) (All-case surveillance) - J-INSPIRE
Contact for Clinical Trial Information0 sites275 target enrollmentNovember 12, 2021
ConditionsCrohn's Disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Crohn's Disease
- Sponsor
- Contact for Clinical Trial Information
- Enrollment
- 275
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients with complex perianal fistulas in Crohn's Disease who received Darvadstrocel will be included.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A post-marketing study of the marketed product Maxtra® P syrup for the evaluation of safety and effects in children having common cold.Health Condition 1: J00- Acute nasopharyngitis [common cold]CTRI/2021/02/031189Zuventus Healthcare Limited200
Completed
Phase 4
A post-marketing study of the marketed product Maxtra® P Tablets for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031390Zuventus Healthcare Limited200
Completed
Not Applicable
postmarketing surveillance For Investigating success in achieving clinical and functional Remission and Sustaining efficacy with Tocilizumab in BIOlogics naive RA patientsPatients with rheumatoid arthritis who have been diagnosed based on the 2010 ACR/EULAR new classification criteria for RA Patients who have no previous medical history of biological agents for RA Patients whose disease activity is DAS28>=3.2 at baselineJPRN-UMIN000006914Chugai Pharmaceutical Co. Ltd.700
Completed
Phase 4
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of basic Fibroblast Growth Factor Compared to Placebo in Combination with NBUVB for the Treatment of VitiligoIRCT20201104049265N1Imen Vaccine Alborz88
Completed
Phase 4
A post marketing study to collect safety data of Gardasil when administered in routine practice to females between 9 to 45 years of ageHealth Condition 1: null- Preventative Cervical CancerCTRI/2015/09/006183MSD Pharmaceuticals PvtLtd